Epidermal Growth Factor Receptor Status in Breast Cancer
Author Information
Author(s): J.R.C. Sainsbury, S. Nicholson, B. Angus, J.R. Farndon, A.J. Malcolm, A.L. Harris
Primary Institution: University of Newcastle upon Tyne
Hypothesis
Is there a relationship between epidermal growth factor receptor (EGFr) expression and histological sub-type in breast cancer?
Conclusion
EGFr positivity is associated with a higher risk of early recurrence and death in breast cancer patients.
Supporting Evidence
- 21% of lobular carcinomas contained EGFr compared to 34% of ductal carcinomas.
- All patients with non-ductal tumors that had detectable EGFr experienced recurrence within 2 years of excision.
- EGFr is a better prognostic variable than oestrogen receptor.
Takeaway
This study found that breast cancer tumors with a specific receptor called EGFr are more likely to come back quickly after treatment.
Methodology
The study analyzed surgically resected breast cancer specimens for EGFr and ER status using immuno-histochemistry and radioligand binding methods.
Limitations
The study is retrospective and may represent an atypical population due to the selection of specimens.
Statistical Information
P-Value
<0.001
Statistical Significance
p<0.001
Want to read the original?
Access the complete publication on the publisher's website